Regeneron Pharmaceuticals, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 3 | $10.17 | $10.17 | $10.17 |
Q2 2024 | 6 | $10.62 | $10.62 | $10.62 |
Q3 2024 | 7 | $11.61 | $11.77 | $11.69 |
Q4 2024 | 16 | $9.01 | $12.83 | $11.00 |
Q1 2025 | 4 | $9.71 | $12.15 | $10.94 |
Q2 2025 | 2 | $11.50 | $13.29 | $12.39 |
Q3 2025 | 2 | $11.98 | $13.84 | $12.91 |
Q4 2025 | 2 | $10.89 | $12.58 | $11.73 |
Regeneron Pharmaceuticals, Inc. Earnings Date And Information
Regeneron Pharmaceuticals, Inc. last posted its earnings results on Thursday, October 31st, 2024. The company reported $12.46 earnings per share for the quarter, topping analysts' consensus estimates of $11.69 by $0.77. The company had revenue of 3.72 B for the quarter and had revenue of 13.12 B for the year. Regeneron Pharmaceuticals, Inc. has generated $37 earnings per share over the last year ($34.77 diluted earnings per share) and currently has a price-to-earnings ratio of 19.25. Regeneron Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, January 31st, 2025 based on prior year's report dates.
Regeneron Pharmaceuticals, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
10/31/2024 | Q3 2024 | $11.69 | $12.40 | 0.71 | $3.67 B | $3.72 B |
08/01/2024 | Q2 2024 | $10.61 | $13.25 | 2.64 | $3.38 B | $3.55 B |
05/02/2024 | Q1 2024 | $10.17 | $6.70 | -3.47 | $3.15 B | |
02/05/2024 | Q4 2023 | $10.88 | $3.43 B | |||
11/02/2023 | Q3 2023 | $10.72 | $9.48 | -1.24 | $3.23 B | $3.36 B |
08/03/2023 | Q2 2023 | $9.84 | $9.05 | -0.79 | $3.02 B | $3.16 B |
05/04/2023 | Q1 2023 | $9.25 | $7.64 | -1.61 | $3.16 B | |
02/06/2023 | Q4 2022 | $11.19 | $3.41 B | |||
11/03/2022 | Q3 2022 | $9.48 | $11.66 | 2.18 | $2.92 B | $2.94 B |
08/03/2022 | Q2 2022 | $8.53 | $7.47 | -1.06 | $2.79 B | $2.86 B |
05/04/2022 | Q1 2022 | $9.74 | $8.61 | -1.13 | $2.97 B | |
02/07/2022 | Q4 2021 | $20.99 | $4.95 B | |||
11/04/2021 | Q3 2021 | $10.10 | $15.37 | 5.27 | $2.75 B | $3.45 B |
08/05/2021 | Q2 2021 | $17.53 | $29.51 | 11.98 | $3.96 B | $5.14 B |
05/06/2021 | Q1 2021 | $9.00 | $10.58 | 1.58 | $2.53 B | |
02/08/2021 | Q4 2020 | $10.90 | $2.42 B | |||
11/05/2020 | Q3 2020 | $7.14 | $7.98 | 0.84 | $2.08 B | $2.29 B |
08/05/2020 | Q2 2020 | $5.98 | $8.19 | 2.21 | $1.73 B | $1.95 B |
05/05/2020 | Q1 2020 | $6.13 | $5.69 | -0.44 | $1.83 B | |
02/07/2020 | Q4 2019 | $7.25 | $2.17 B |
Regeneron Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Regeneron Pharmaceuticals, Inc.'s earnings date?
Regeneron Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, January 31st, 2025 based off last year's report dates.
-
Did Regeneron Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Regeneron Pharmaceuticals, Inc. (:REGN) reported $12.46 earnings per share (EPS) to beat the analysts' consensus estimate of $11.69 by $0.77.
-
How can I listen to Regeneron Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Regeneron Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Regeneron Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Regeneron Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Regeneron Pharmaceuticals, Inc. generate each year?
Regeneron Pharmaceuticals, Inc. (:REGN) has a recorded annual revenue of $13.12 B.
-
How much profit does Regeneron Pharmaceuticals, Inc. generate each year?
Regeneron Pharmaceuticals, Inc. (:REGN) has a recorded net income of $13.12 B. Regeneron Pharmaceuticals, Inc. has generated $37.05 earnings per share over the last four quarters.
-
What is Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio?
Regeneron Pharmaceuticals, Inc. (:REGN) has a price-to-earnings ratio of 19.25 and price/earnings-to-growth ratio is 2.66.